Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals

Breast Cancer Therapeutics Market by Drug Classes – Brand Name (Chemical Name) – Antimetabolites – Gemzar (Gemcitabine), Aromatase Inhibitors – Afinitor (Everolimus), Arimidex (Anastrozole), Aromasin (Exemestane), Femara (Leterozole), Ibrance (Palbociclib); Her2 Inhibitors – Herceptin (Trastuzumab), Kadcyla (Ado-Trastuzumab Emtansine), Perjeta (Pertuzumab), Tykerb (Lapatinib); Hormone Receptors –  Fareston, Faslodex, Zoladex; and Mitotic Inhibitors – Halaven (Eribulin), Ixempra (Ixabepilone), Taxotere (Docetaxel) and Forecast 2024-2031


Report Specifications: Market Size, Market Share, Growth Trends, Forecast, Geography

Breast cancer therapeutics include hormone therapies, signal transduction inhibitors, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, and toxin delivery molecules. Breast cancer is the most common type of invasive cancer affecting women, and it is the most common cause of cancer death among women worldwide. It usually originates from the inner lining of milk ducts or lobules responsible for supplying the milk. The malignant type of tumor can spread to other cells present in the body. North America dominates market share for breast cancer therapeutics considering highest prevalence rate, modern medical technologies, health insurance coverage, and optimum per capita income.

The global breast cancer therapeutics market report estimates the market size ($million 2021 to 2031) for key market segmented by the drug classes – brand name (chemical name) such as antimetabolites – Gemzar (gemcitabine), aromatase inhibitors – Afinitor (everolimus), Arimidex (anastrozole), Aromasin (exemestane), Femara (leterozole), Ibrance (palbociclib); Her2 Inhibitors – Herceptin (trastuzumab), Kadcyla (ado-trastuzumab emtansine), Perjeta (pertuzumab), Tykerb (lapatinib); Hormone receptors –  Fareston, Faslodex, Zoladex; and Mitotic inhibitors – Halaven (eribulin), Ixempra (ixabepilone), Taxotere (docetaxel), and forecast (CAGR%, 2024 to 2031).

The global breast cancer therapeutics market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global breast cancer therapeutics market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.

Major players operating in the global breast cancer therapeutics market and included in this report are AstraZeneca plc, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis International AG, Pfizer, Inc., Puma Biotechnology, Sanofi S.A., Teva Pharmaceutical Industries Ltd.

DATA INCLUDED: Breast Cancer Therapeutics Market Size, Breast Cancer Therapeutics Market Share, Breast Cancer Therapeutics Market Growth Rates, Breast Cancer Therapeutics Market Trends, and Breast Cancer Therapeutics Market Forecast to 2031

Market Data:

  • Base year for estimation: 2023
  • Actual estimates/Historical data: 2021-2031
  • Forecast period: 2024-2031
  • Market representation: Revenue in $million and CAGR % from 2024 to 2031
  • Regional scope: North America, Europe, Asia Pacific, Latin America, Rest of the World (Middle East & Africa)
  • Country scope: U.S., Canada, U.K., Germany, France, Italy, Spain, Japan, China, India, South Korea, Brazil, Mexico, South Africa, South Korea, Saudi Arabia, UAE and others.
  • Report coverage: Revenue forecast, company share, competitive landscape, growth factors, and trends
  • 15% free customization scope: Any specific or custom requirements, which is not currently within the scope of the report, will be provided as a part of customization.

Qualitative Analysis:

  • Industry overview
  • Industry trends
  • Market drivers and restraints
  • Key market opportunities
  • Market size
  • Growth trends
  • Porter’s five forces analysis
  • Market attractiveness analysis
  • Competitive landscape
    • Company overview
    • Financial performance
    • Product portfolio
    • Strategic insights
    • Recent developments

Quantitative Analysis:

  • Market size estimates and forecast for all segments
  • Regional market size estimated and forecast for major countries
  • Company financial performance
  • Competitive landscape: Company market share analysis

Please contact us for offers on individual or multiple report purchases.

  1. Introduction
  2. Executive Summary
    • Market Size Estimation ($million, 2021-2031)
    • Forecast Estimation ($million and CAGR%, 2024-2031)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2031)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Key Questions Answered:
1. What are the factors driving and limiting this market, key success factors and challenges?
2. Which are the leading competitors in the market, their market share, profitability and key trends by product, technology, services portfolio?
3. How do markets perform between countries and regions?
4. What market segments are contributing to maximum share and greatest growth?
5. What are the product or procedure volumes by country and regions?

Actionable Insights Included:
1. Product portfolio matrix (Share vs. Growth)
2. Market attractiveness (Region vs. Growth)
3. Spot matrix (Product vs. Region)
4. Geographic distribution matrix (Share vs. Growth)

Breast Cancer Therapeutics Market

1. Drug Class
1.1. Anti-metabolites
1.1.1. Gemzar (Gemcitabine)
1.2. Aromatase Inhibitors
1.2.1. Afinitor (Everolimus)
1.2.2. Arimidex (Anastrozole)
1.2.3. Aromasin (Exemestane)
1.2.4. Femara (Leterozole)
1.2.5. Ibrance (Palbociclib)
1.3. HER2 Inhibitors
1.3.1. Herceptin (Trastuzumab)
1.3.2. Kadcyla (Ado-trastuzumab emtansine)
1.3.3. Perjeta (Pertuzumab)
1.3.4. Tykerb (Lapatinib)
1.4. Hormone Receptor
1.4.1. Fareston
1.4.2. Faslodex
1.4.3. Zoladex
1.5. Mitotic Inhibitors
1.5.1. Halaven (Eribulin)
1.5.2. Ixempra (Ixabepilone)
1.5.3. Taxotere (Docetaxel)

2. Company Profiles
2.1. AstraZeneca plc
2.2. Eisai Co., Ltd.
2.3. Eli Lilly and Company
2.4. F. Hoffmann-La Roche Ltd.
2.5. GlaxoSmithKline plc
2.6. Novartis International AG
2.7. Pfizer, Inc.
2.8. Puma Biotechnology, Inc.
2.9. Sanofi S.A.
2.10. Teva Pharmaceutical Industries Ltd.

    Request ToC / Sample Report

    Full Name*

    Company Email*

    Phone Number* [Please add country code]



    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: sales@ihealthcareanalyst.com